Keyphrases
Phase II Study
100%
Polycythemia Vera
100%
Post-essential Thrombocythemia Myelofibrosis
100%
Simtuzumab
100%
Ruxolitinib
45%
Bone Marrow Fibrosis
27%
Clinical Benefit
18%
Treatment Group
9%
Pyrexia
9%
Infusion Reaction
9%
Number of Patients
9%
Monoclonal Antibody
9%
Fibrosis Score
9%
Serious Adverse Events
9%
Lysyl Oxidase
9%
Mg Treatment
9%
Myelofibrosis
9%
Trough Concentration
9%
Therapy-related
9%
Primary Myelofibrosis
9%
Antibody Inhibition
9%
Extracellular Matrix Enzymes
9%
Pharmacology, Toxicology and Pharmaceutical Science
Polycythemia vera
100%
Myelofibrosis
100%
Thrombocythemia
100%
Simtuzumab
100%
Ruxolitinib
45%
Fever
9%
Adverse Event
9%
Clinical Study
9%
Monoclonal Antibody
9%
Myeloid metaplasia
9%
Protein Lysine 6 Oxidase
9%
Treatment Group
9%
Immunology and Microbiology
Simtuzumab
100%
Extracellular Matrix
9%
Monoclonal Antibody
9%
Trough Concentration
9%
Drug Dose Increase
9%